<DOC>
	<DOCNO>NCT00304616</DOCNO>
	<brief_summary>To evaluate efficacy , safety tolerance 12 26-week aripiprazole administration</brief_summary>
	<brief_title>SWitching Abilify Trial ( SWAT )</brief_title>
	<detailed_description>This trial design evaluate efficacy , safety tolerance 12 26-week aripiprazole administration schizophrenic outpatient maintain stable ( change dosage , usage , route recent antipsychotic drug ) symptom discontinue previous antipsychotic drug . Aripiprazole ( 10~30 mg/day ) orally administer 12 week follow extension phase maximum additional 14 week ( total 26 week ) .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Signed write informed consent Men woman , age 18 65 . Women childbearing potential ( WOCBP ) must use adequate method contraception avoid pregnancy throughout study manner risk pregnancy minimize . Patients hospitalize last three month Patients keep clinically stable dosage last one month Patients diagnosis schizophrenia schizoaffective disorder define DSMIV criterion Patients whose symptom optimally control whose antipsychotic medication welltolerated , clinical judgment treat psychiatrist require change treatment . Patients receive antipsychotic past must show response neuroleptic medication clozapine . Patients unwilling unable use acceptable method avoid pregnancy entire study period Women pregnant breastfeeding Patients risk commit suicide : either active suicidal ideation consider clinically significant recently attempt suicide Patients diagnosis bipolar disorder , depression psychotic symptom , organic brain syndrome Patients meet DSMIV criterion significant Psychoactive Substance Use Disorder within 3 month prior Screening Patients consider treatmentresistant antipsychotic medication ( patient need show previous response antipsychotic medication clozapine ) patient significant history intolerance multiple antipsychotic treatment Treatment longacting antipsychotic ( i.e. , haloperidol decanoate fluphenazine decanoate ) last dose within 3 week randomization . Patients history neuroleptic malignant syndrome Patients epilepsy , history seizure ( except single childhood febrile seizure ) , history abnormal EEG , severe head trauma , stroke history evidence medical condition ( e.g. , congestive heart failure ) would expose undue risk significant adverse event interfere assessment safety efficacy course trial Patients would likely require prohibited concomitant therapy trial Patients previously enrol aripiprazole clinical study participate clinical trial investigational agent within past month Prisoners subject compulsorily detain treatment either psychiatric physical ( e.g. , infectious disease ) illness must enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Aripiprazole</keyword>
</DOC>